Combined dipeptidyl peptidase-4 inhibitor with low-dose testosterone exerts greater efficacy than monotherapy on

Puntarik Keawtep1, Wasana Pratchayasakul1, Apiwan Arinno1

  • 1Neurophysiology Unit, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; Center of Excellence in Cardiac Electrophysiology Research, Chiang Mai University, Chiang Mai, Thailand.

Insights

Combined low-dose testosterone replacement therapy (TRT) and vildagliptin show promise for improving brain health and cognition in orchiectomized-obese rats. This combination therapy offers a potential therapeutic strategy for this complex condition.

Area of Science:

  • Neuroscience
  • Endocrinology
  • Metabolic Syndrome

Background:

  • Obesity and orchiectomy independently contribute to brain pathologies and cognitive decline.
  • Existing treatments like testosterone replacement therapy (TRT) and vildagliptin show benefits in individual conditions but not in the combined orchiectomized-obese state.
  • High-dose TRT can mitigate brain defects but carries adverse effects, necessitating investigation into alternative therapeutic combinations.

Purpose of the Study:

  • To investigate the combined effects of low-dose TRT (1 mg/kg/day) and vildagliptin on brain function and cognitive performance in orchiectomized-obese rats.
  • To determine if this combination therapy can overcome the limitations of monotherapies in addressing neuroinflammation, oxidative stress, and cognitive deficits.

Main Methods:

  • Sixty male rats were fed either a normal diet (ND) or a high-fat diet (HFD) for 28 weeks.
  • Orchiectomy or sham-operation was performed at week 13.
  • At week 25, orchiectomized rats received vehicle, 2 mg/kg/day TRT, 3 mg/kg/day vildagliptin, or a combination of 1 mg/kg/day TRT and vildagliptin for 4 weeks.

Main Results:

  • Orchiectomy aggravated hippocampal oxidative stress, apoptosis, dendritic spine loss, microglial hyperactivity, and cognitive decline in HFD-fed rats.
  • While monotherapies partially ameliorated these brain pathologies in orchiectomized HFD-fed rats, the combined therapy demonstrated the most significant beneficial effects.
  • All tested treatments restored brain and cognitive functions in orchiectomized ND-fed rats.

Conclusions:

  • Combined low-dose TRT and vildagliptin therapy is a promising approach for restoring brain function and cognitive performance in orchiectomized-obese rats.
  • This combination therapy may offer a superior therapeutic strategy compared to monotherapies for addressing the complex neurobiological consequences of combined obesity and orchiectomy.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
618
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
238
Testosterone: Functions and Regulation01:26

Testosterone: Functions and Regulation

The intricate hormonal interplay essential for male reproductive health begins with the release of gonadotropin-releasing hormone (GnRH) by the hypothalamus. This hormone prompts the pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). LH targets the Leydig cells in the testes, stimulating them to produce and release testosterone. In concert with testosterone, FSH acts on the Sertoli cells within the seminiferous tubules to facilitate the release of...
2.1K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.4K
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.2K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.9K